July 7, 2002

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832



BURLINGTON, MA  Sunday, July 07, 2002 – ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices which provide pacing and defibrillation, today announced that preliminary revenues for the third quarter ending June 30, 2002 would be approximately $34.5 million. This level of sales would represent only a modest 14% increase over the prior year period. Resulting preliminary earnings per share will also likely only grow modestly in a range of $0.19 to $0.22, lower than the First Call consensus of $0.28. A conference call will be conducted at 9:00 a.m. on Monday, July 8, 2002 to discuss these results.

Richard A. Packer, President and Chief Executive Officer, explained, “Our results for the third quarter were constrained by an unexpected production problem with our M Series line of monitor/defibrillators. We were unable to complete and ship the units needed to match the orders we received at the end of the quarter. As a result we found ourselves with an unexpected incremental backlog of M Series orders, representing over 200 units, at the close of the quarter. This production problem was short lived, but occurred in the last few days of the quarter and we were unable to make up the time. M Series are now shipping normally and we are clearing out the backlog of customer orders. This is a very unusual circumstance for ZOLL, as I cannot recall another time where we had the orders in our backlog to achieve our desired growth, but were unable to produce and ship the units.”

Mr. Packer continued, “Unfortunately this production problem overshadows what would have been another strong quarter of growth for ZOLL. Orders in the US hospital segment continued to be very strong. The International segment also had a strong quarter for orders. Our new AED Plus product has been well received, with over 2000 units booked during the quarter and approximately 600 units shipped during the latter part of the quarter. Therefore, the underlying business remains strong, and while we will likely show growth in both sales and earnings over the prior year, we were obviously disappointed that our production execution fell short.” The company plans to report final financial results and normal segment information on Thursday, July 18, 2002.

Mr. Packer concluded with this outlook, “On the strength of the orders received during the third quarter, we continue to believe that we will hit our targets for the year. We expect that the fourth quarter will be strong for ZOLL, as is normally the case. In addition, the product that was not shipped in the third quarter will be added on top of the regular fourth quarter shipments. We have put this production issue quickly behind us and we expect to resume our strong growth.”

If you are interested in listening to the conference call, please dial 630-395-0411 at 9:00 a.m. Eastern Standard Time and reference pass code “ZOLL”. The conference call leader will be Mr. Richard Packer, President and Chief Executive Officer of ZOLL. The company may answer one or more questions concerning business and financial developments and trends, the company’s view on earnings forecasts and other business and financial matters affecting the company, some of the responses to which may contain information that has not yet been previously disclosed.

About ZOLL
ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation – pacing and defibrillation – these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software that automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands and Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit the ZOLL web site at www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, the intent, belief or current expectations of the Company, its directors or its officers, primarily with respect to the Company's business model and future operating performance of the Company, including expectations regarding results in future periods, operating performance and contributions to results from the Company’s new Public Access Defibrillation product, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-Q filed on May 15, 2002, the future performance of the direct sales operations, the outcome of a pending patent infringement suit relating to the ZOLL AED Plus, as well as uncertainties regarding the market, acceptance and profitability of the ZOLL AED Plus, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital markets, the potential disruption in the transportation industry on the Company’s supply chain and product distribution channels, and the desire or ability of other parties to purchase the Company's products.